Down Rounds in India: Why Valuations Collapse, How Investors Can Protect Themselves, and the Legal Fallout for Companies

Byadmin

1.  The Trigger: SUGAR Cosmetics

The recent SUGAR Cosmetics round — ₹144.5 crore raised from A91 Partners at a ₹755 crore valuation, roughly 75% below its 2022 peak of ~₹3,000 crore, alongside FY25 revenue falling 20% to ₹404 crore and losses nearly doubling to ₹135 crore — is a textbook “down round.” It is not an isolated event. Byju’s, PharmEasy, Ola and several other Indian unicorns have been through the same cycle. This note examines why this happens, what legal and contractual consequences follow for the company and its founders, and what investors should build into their documentation to limit exposure to it.

2.  What Is a “Down Round”

A down round is a financing round in which new shares are issued at a price per share lower than the price paid in the immediately preceding round, resulting in a lower post-money valuation than the prior round’s post-money (or, in secondary markdowns, a lower fair value ascribed by an existing investor). It is distinct from, but often triggers, a “markdown” — where an existing investor (mutual fund, PE/VC, or sovereign fund) unilaterally revalues its holding downward for its own NAV/portfolio reporting without a fresh transaction.

3.  What Causes the Collapse in Valuation

  1. Company-Specific / Governance Causes
  • Aggressive, debt-funded or overpriced acquisitions made during a growth-at-all-costs phase, later proving to be poor capital allocation
  • Revenue recognition irregularities or delayed / qualified audited financials, which destroy investor confidence in reported numbers
  • Founder-board conflict, whistleblower complaints, or forensic audit findings of financial irregularity
  • Loan covenant breaches forcing a distress equity raise (rights issue) to repay lenders, on terms dictated by whoever is willing to fund the shortfall
  • Unsustainable customer acquisition cost / burn relative to unit economics, with losses widening even as revenue growth slows or reverses
  • ESOP-heavy cap tables and founder dilution that reduce the perceived alignment of the people running the company
  1. Market / Macro Causes
  • Global “funding winter” — a sharp contraction in risk capital and rise in the cost of capital, compressing revenue and growth multiples across the board
  • Increased competitive intensity compressing margins in categories (such as D2C beauty, edtech, e-pharmacy) that once commanded frothy multiples on the assumption of continued hypergrowth
  • Pandemic-era demand pull-forward reversing once normalcy returns (most visible in edtech and e-pharmacy)
  • Public market comparables re-rating downward, which pulls private valuations down with a lag as later-stage and pre-IPO investors mark to market
  1. Structural Causes Embedded in the Cap Table
  • Existing investors using a distress situation (loan default, cash-out need) to reset the entry price for themselves via a rights issue or internal round, effectively “calling the shots,” as happened with PharmEasy
  • Down rounds triggering anti-dilution ratchets in favour of earlier preferred investors, which further dilutes founders and ESOP holders beyond the headline price cut

4.  Real Examples and What They Show

Byju’s

Valued at $22 billion in early 2022, Byju’s saw BlackRock cut the implied valuation of its holding to about $1 billion, a roughly 95% markdown, while Prosus wrote its stake down to zero in its FY24 annual report, citing inadequate visibility into the company’s financial health and liabilities. The proximate causes were an acquisition spree — including Aakash Educational Services for close to $950 million — combined with governance failures and repeatedly delayed audited results. This illustrates how M&A overreach plus disclosure failures compound to destroy value even for a category leader.

PharmEasy (API Holdings)

From a peak of $5.6 billion in October 2021, PharmEasy raised roughly ₹1,804 crore from Ranjan Pai’s family office in a rights issue representing a 90% valuation cut. The trigger was a lender covenant breach: Goldman Sachs had extended debt on condition that PharmEasy complete a ₹1,000 crore equity round, which did not materialise, forcing the distressed rights issue. Crucially, the down round triggered anti-dilution clauses in several investors’ agreements, and ESOP holders and founders — who had no right to participate at the discounted price — faced disproportionate dilution, prompting the board to consider fresh ESOP grants to offset the erosion. This is the clearest recent Indian illustration of contractual anti-dilution mechanics converting a business problem into a founder/ESOP-holder wealth transfer.

Zilingo

A near-$1 billion Singapore/India-linked fashion-tech unicorn backed by Temasek, Sequoia and Burda. The company terminated founder-CEO Ankiti Bose following an independent forensic investigation into alleged financial irregularities, and investor Burda Principal Investments publicly attributed the company’s failure to significant irregularities in reporting to investors, signalling it was weighing legal action. The company subsequently went into liquidation, and years later a criminal GST-fraud complaint and multiple defamation suits between the founder and investors were still working through Indian and Singapore courts. This is the strongest illustration of how a valuation collapse rooted in accounting irregularity escalates into forensic audits, “for cause” employment termination, criminal complaints, and protracted litigation — not just a lower share price.

Common thread across all three: none of the erosion happened purely because “the market turned.” In each case, aggressive capital deployment, governance or disclosure gaps, and lender/investor leverage in a down cycle converted a valuation correction into a structural — and in Zilingo’s case criminal — event.

5.  Legal Consequences a Company May Face

  1. Contractual Consequences (Shareholders’ Agreement / Share Subscription Agreement)
  • Anti-dilution adjustment — full-ratchet or (more commonly in India) broad-based weighted-average anti-dilution clauses under the SHA automatically reprice or top up the shareholding of existing preferred investors, diluting founders and ESOP pool holders without any fresh consideration from those investors.
  • Breach of representations and warranties / MAC clauses — if the down round follows a discovery that earlier reps and warranties on financials, litigation, or compliance were inaccurate, existing investors can claim indemnification, or in extreme cases, rescission or damages.
  • Liquidation preference stacking — new down-round investors typically insist on senior, participating liquidation preferences, which can leave little or nothing for common/ESOP holders even in a reasonable exit.
  • Protective provisions / veto triggers — a rights issue or down round frequently requires investor consent under reserved matters clauses; proceeding without it exposes the company and its directors to breach-of-contract claims.
  1. Companies Act, 2013
  • Pricing compliance for preferential allotment — Section 62(1)(c) read with Rule 13 of the Companies (Share Capital and Debentures) Rules requires a registered valuer’s report to support the issue price; a down round must be defensible on a proper valuation, or the allotment is open to challenge.
  • Oppression and mismanagement (Sections 241–242) — minority shareholders (including founders diluted by a ratchet, or minority investors who did not get pro-rata rights in a rights issue) can petition the NCLT alleging the affairs of the company were conducted in a manner prejudicial to their interests.
  • Fraud and misstatement (Sections 447, 448) — where the valuation collapse traces back to inflated revenue reporting or false statements to the board/auditors/ROC, promoters and officers face criminal liability, including imprisonment, under Section 447 (a non-bailable, cognizable offence above certain thresholds).
  • Director’s fiduciary duty (Section 166) — directors who approved acquisitions, related-party transactions, or a distress round without exercising independent judgment can be held personally liable for breach of duty.
  1. FEMA / RBI Pricing Norms

Any fresh issue of shares to a non-resident investor (or transfer of existing shares) must comply with the pricing guidelines under the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 — the issue price cannot be lower than the fair value determined under an internationally accepted valuation methodology (typically DCF) certified by a merchant banker/chartered accountant. A steep down round needs to be independently supportable on this valuation, or the company risks a FEMA contravention flagged in RBI compounding proceedings.

  1. SEBI (For Listed or Soon-to-List Entities)

Where a company that has undertaken a down round is listed, or is in an IPO process (as PharmEasy and Byju’s both once were), misstatement of financials in offer documents attracts SEBI action under the ICDR Regulations and the SEBI Act — including disgorgement, debarment of promoters/directors, and referral for prosecution.

  1. Insolvency and Bankruptcy Code, 2016

If the down round was a forced response to a lender covenant breach (as with PharmEasy’s Goldman Sachs debt) and the raise fails or is inadequate, the company faces insolvency proceedings under Section 7 (financial creditor default). Directors who continued trading while insolvent, or diverted funds, face liability for fraudulent/wrongful trading under Sections 66 and 67.

  1. Employment and ESOP-Related Claims

ESOP holders diluted without an opportunity to participate in a rights issue (as flagged in the PharmEasy situation) may raise claims for breach of the ESOP scheme’s terms or the employment contract, particularly where the scheme document promised anti-dilution protection that was not honoured.

  1. Income-Tax Exposure

A valuation materially below the fair market value determined under Rule 11UA can — subject to the current exemptions for DPIIT-recognised startups and the FY2024-25 abolition of angel tax under Section 56(2)(viib) for resident investors — still create exposure for non-qualifying issuances or for the receiving shareholder in certain fact patterns. This should be checked issuance-by-issuance rather than assumed exempt.

6.  What Investors Should Do to Protect Against Devaluation Risk

  1. Structure real anti-dilution protection at entry — insist on broad-based weighted-average anti-dilution (full ratchet only where leverage allows), clearly drafted to survive a distress rights issue, not just an ordinary down round.
  2. Tie tranches to milestones — stagger investment across performance-linked tranches rather than a single upfront cheque, so capital at risk scales with demonstrated execution.
  3. Negotiate information and audit rights — monthly MIS, board observer or seat rights, and the right to commission an independent forensic/financial audit on trigger events (covenant breach, auditor resignation, restatement).
  4. Build in affirmative and negative covenants — restrict large acquisitions, related-party transactions, and further indebtedness above a threshold without investor consent.
  5. Price protection via structured instruments — consider CCPS/CCDs with defined conversion mechanics and a floor, rather than pure equity, so downside is contractually bounded.
  6. Pro-rata and participation rights — ensure a contractual right to participate in any future round (including rights issues) at the same terms, so a later distress raise cannot be used to squeeze out existing minority investors.
  7. Reserved matters / veto rights — require investor consent for any preferential allotment, rights issue, or change in ESOP pool size, so a board cannot approve a dilutive down round unilaterally.
  8. Independent valuation on every round — do not rely solely on the company’s numbers; commission an independent registered-valuer opinion, particularly before a distress round, to test the basis for the proposed price.
  9. Pre-investment legal and financial due diligence depth — verify revenue recognition policy, related-party transactions, litigation history, and covenant terms on existing debt before committing, since most of the examples above trace back to gaps that diligence should have caught.
  10. Exit and liquidation preference discipline — negotiate liquidation preference and seniority carefully; in a later down round, new money will demand seniority, so early investors should pre-negotiate anti-stacking protections where possible.

7.  Practical Note for Founders and Companies

  • Maintain audited, timely financials and avoid delaying statutory filings — most valuation collapses examined above were preceded or accompanied by delayed or restated financials.
  • Model the anti-dilution and ESOP-pool impact of a hypothetical down round before it becomes necessary, so the board understands the true cost of a distress raise.
  • Where a rights issue is unavoidable, negotiate a compensatory ESOP top-up or a carve-out for founders/employees to participate, to avoid downstream disputes and claims.
  • Obtain board legal advice before triggering any protective provision or reserved matter under the SHA — proceeding without required consents is one of the more common and avoidable sources of post-facto litigation.

This note is for general information and does not constitute legal advice on any specific transaction. Every down round should be assessed against the specific SHA/SSA, ESOP scheme, and applicable regulatory framework governing that company.

© VNC Corporate & Legal, Advocates & Solicitors